NRG Oncology

The NRG-BN001 Phase II trial demonstrated that proton therapy at 75 Gy improved overall survival in newly diagnosed glioblastoma patients compared to standard photon therapy.

The phase II BALANCE trial validated PAM50 as the first predictive biomarker for hormone therapy response in recurrent prostate cancer, identifying patients with luminal B tumors who benefit significantly from apalutamide treatment.

The phase 3 PREDICT-RT trial has successfully enrolled 2,478 patients across US and Canada to test individualized treatment approaches for high-risk prostate cancer using Decipher genomic testing.

The phase 3 ARCHER trial (NRG-GU015) is now enrolling 486 patients to compare ultra-hypofractionated stereotactic body radiation therapy (5 treatments) versus standard hypofractionated radiotherapy (20 treatments) for muscle invasive bladder cancer.

The NRG-BR003 phase 3 trial found that adding carboplatin to standard paclitaxel and doxorubicin/cyclophosphamide chemotherapy did not provide statistically significant improvements in survival outcomes for triple-negative breast cancer patients.

The NRG-NSABP B-51/RTOG 1304 trial found that regional nodal irradiation does not reduce invasive breast cancer recurrence in patients whose axillary nodes converted from positive to negative after neoadjuvant chemotherapy.

• Flatiron Health and NRG Oncology have partnered to implement Flatiron Clinical Pipe, an EHR-to-EDC connector technology, in a multi-center oncology trial to enhance data entry efficiency. • The technology enables rapid transfer of thousands of data points directly from electronic health records, eliminating the need for source data verification and potentially reducing administrative burden on research staff. • A correlative study will be conducted alongside the implementation to evaluate the efficiency of Flatiron Clinical Pipe compared to traditional data entry methods in clinical trials.

Cortechs.ai and EDAP TMS SA achieved a milestone with the first-ever OnQ Prostate-assisted Focal One Robotic HIFU procedure performed at UCSF Prostate Center.

Financial hardship affects 50-70% of cancer patients in community settings, leading to treatment adherence issues and worse outcomes, particularly among underserved populations.

A phase II trial (NRG-RTOG1106/ECOG-ACRIN 6697) investigated whether midtreatment FDG-PET/CT-guided adaptive radiation therapy (RT) could improve outcomes in stage III non-small cell lung cancer (NSCLC).